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In this study we have evaluated the changes in arterial blood pressure in spontaneously
hypertensive rats (SHR) caused by the short-term intake of Bacillus subtilis B060-fermented
beans with significant g-aminobutyric acid (GABA) and nattokinase activity. After being
weaned, 7-week-old male SHR and 7-week-old male WistareKyoto (WKY) rats were ran-
domized into seven groups. Until the 8th week of life, the rats in each group were given one
of the following: Group 1, high dose of GABA and nattokinase in the SHR (SHD); Group 2,
medium dose of GABA and nattokinase in the SHR (SMD); Group 3, low dose of GABA and
nattokinase in the SHR (SLD); Group 4, negative control in the SHR (SD); Group 5, positive
control in the SHR (SM); Group 6, high dose of GABA and nattokinase in the WKY (WHD);
and Group 7, negative control in the WKY (WD). Distilled water served as the negative
control, and captopril (50 mg/kg), a known ACE inhibitor, served as the positive control.
Systolic blood pressure and diastolic blood pressure values were measured weekly from
the 8th week to the 16th week of life using the tail-cuff method. A definite decrease in
systolic and diastolic blood pressure values could be observed in the rats treated with
captopril and in the rats that received GABA and nattokinase. The greatest antihyperten-
sive effect was observed when the pharmacological treatment was administered. The ef-
fect of the daily intake of fermented beans containing GABA and nattokinase may be
helpful in controlling blood pressure levels in hypertensive model animals. The fermen-
tation of beans with B. subtilis B060 may therefore constitute a successful strategy for
producing a functional food with antihypertensive activity.
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Recently, the relationship between food and health has drawn
considerable attention; of specific interest are the physiolog-
ical actions of food components against certain ailments.
Hypertension is a worldwide problem of epidemic propotions
and presents in 15e20% of all adults. It is the most common
serious chronic health problembecause it carries a high risk of
cardiovascular complication [1]. As an insidious and ubiqui-
tous disease, hypertension and its complications may
contribute to the deaths of 1.5 million and the disability of
another 1.5 million Americans each year [1]. Hypertension is
associated with increased vascular oxidative stress and signal
transduction; however, there is still a debate whether oxida-
tive stress and signal transduction are a cause or a result of
hypertension. Animal studies have generally supported the
hypothesis that increased blood pressure (BP) is associated
with increased oxidative stress and signal transduction;
however, human studies have been inconsistent. Oxidative
stress and signal transduction promote vascular smooth
muscle cell proliferation and hypertrophy and collagen
deposition, leading to thickening of the vascular media and
narrowing of the vascular lumen. In addition, increased
oxidative stress and signal transduction may damage the
endothelium and impair endothelium-dependent vascular
relaxation and increases vascular contractile activity. All
these effects on the vasculature may explain how increased
oxidative stress and signal transduction can cause hyperten-
sion. Treatment with antioxidants has been suggested to
lower oxidative stress, signal transduction, and therefore, BP.
However, to date, clinical studies investigating antioxidant
supplements have failed to show any consistent benefit. It is
noteworthy that lowering BP with antihypertensive medica-
tions is associated with reduced oxidative stress and signal
transduction [2]. Moreover, it has been suggested that hyper-
tension is closely related to the components of food, specif-
ically sodium chloride and protein, and that antihypertensive
peptides may contain an antihypertensive peptide motif.
Some bioactive peptides are angiotensin-converting
enzyme inhibitors (ACEIs), and they may be used for pre-
venting hypertension and for other therapeutic purposes [3].
Although most ACEI peptides have been detected in func-
tional dairy products, some have recently been identified and
characterized from cereal proteins. In addition to ACEI pep-
tides, g-aminobutyric acid (GABA) also shows potential for
lowering BP in spontaneously hypertensive rats (SHR) and
hypertensive humans [4]. GABA, a nonprotein amino acid,
possesses well-known physiological functions, such as
neurotransmission, induction of hypotension, and diuretic
and tranquilizer effects [5]. GABA is synthesized by the irre-
versible a-decarboxylation of L-glutamate by glutamic acid
decarboxylase. Several GABA-enriched cereal foods have been
characterized, including rice germ soaked in water, germi-
nated brown rice treated by high-pressure, germinatedwheat,
and red mold rice [5].
Natto is a traditional soybean-fermented food from Japan
and contains nattokinase. Kim et al [6] tested the effect of
nattokinase on BP for a large number of participants (n ¼ 86)
with prehypertension or stage 1 hypertension and observed areduction in systolic blood pressure (SBP) and diastolic blood
pressure (DBP) from nattokinase supplementation. The result
of this trial has suggested that nattokinase supplementation
may be beneficial for hypertension. However, the mechanism
by which nattokinase prevents hypertension, particularly the
necessity of protease activity, has not yet been revealed. Pro-
teins are, in general, decomposed into peptides or amino acids
under the action of digestive enzymes, such as trypsin,
chymotrypsin, and carboxypeptidase, in the intestines. By
contrast, a previous study using rats has shown that natto-
kinase escapes the action of digestive enzymes, is absorbed
by the small intestine, and cleaves fibrinogen directly in
plasma [7].
In this study, both GABA and nattokinase were obtained
from fermented beans with a starter culture containing Ba-
cillus subtilis B060. The effects of the administration of GABA
and nattokinase on lowering BP in SHR were investigated. To
facilitate the interpretation of our results, we also measured
the gain in weight and the consumption of solid, freely
accessible feed by the animals.2. Methods
2.1. Bacteria and fermentations
B. subtilis B060 was used in the present study to produce fer-
mented beans with GABA and nattokinase. This microor-
ganism was maintained as a stock culture in agar slants of
Tryptic soy agar (Merck, Darmstadt, Germany).
Precultures of B. subtilis B060were prepared from 10% yeast
extract, 4% fructose, 0.3% CaCl2, 0.5% NaCl, and 0.25% K2HPO4
for the production of nattokinase and from 0.3% yeast extract,
0.1% fructose, 1% monosodium glutamate, 0.5% NaCl, and
0.25% K2HPO4 for the production of GABA. The desired
mixture was heated to 121C for 15 min, cooled to 42C, and
inoculated with a loop of the stock culture to yield an initial
bacterial concentration of 105e107 colony-forming units/mL.
Incubation was performed at 37C for 18 hours in a shaking
incubator. This preculturewas used to inoculate the bean base
to obtain the stock of fermented beans.
Black beans, soybeans, and wheat bran were purchased
from a local market and used as the substrate for GABA and
nattokinase production under solid-state cultivation; the op-
timum mixing ratio was 1:1:1 (w/w/w). Except for the param-
eters under investigation, the substrates were prepared as
follows. Beans were soaked in distilled water for 8 hours, and
then the water was removed. The soaked beans were auto-
claved for 15 minutes at 121C. After cooling, the substrates
were inoculated with a 2% (v/w) bacterial suspension of B.
subtilis B060 and incubated at 37C overnight. The maximum
yields of GABA and nattokinase were 22.07 mg/g and 146.70
units/g, respectively. The fermented beans were blended with
distilled water, centrifuged, and finally lyophilized. The final
product was the GABA and nattokinase powder.
2.2. Experimental procedure in rats
Thirty male SHR (7 weeks old) and 12 male WistareKyoto
(WKY) rats (7 weeks old) were purchased from BioLASCO
Table 1 e Dietary consumption and body weight gain of rats in the experimental groups.*
SHR SMD SLD SD SM WHD WD
Diet consumption
(g/cage/wk)
373.50  0.048e 403.83  0.004b 394.50  0.006c 409.84  0.006* 388.61  0.004d 346.20  0.004g 366.39  0.004f
Body weight gain
(g/wk)
10.14  0.007g 10.98  0.005f 11.32  0.012d 11.62  0.007c 11.19  0.006e 14.33  0.007b 15.04  0.005*
Different letters indicate a significant difference (p < 0.05, mean  SD).
* Animals were divided into the following seven groups: Group 1, high dose of g-aminobutyric acid (GABA) and nattokinase in the SHR (SHD);
Group 2, medium dose of GABA and nattokinase in the SHR (SMD); Group 3, low dose of GABA and nattokinase in the SHR (SLD); Group 4,
negative control in the SHR (SD); Group 5, positive control (SM); Group 6, high dose of GABA and nattokinase in the WKY(WHD); Group 7,
negative control in the WKY (WD). Rats divided into each group were housed three per cage throughout the experiment.
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individual cages in a room under controlled 12 hours light-
edark cycles at 25  1C and a relative humidity of 55  5%.
During the experimental period, the rats were fed a solid
standard diet for rats (Labdiet 5001; St. Louis, MO, USA). The
rats were divided into seven groups: Group 1, high dose of
GABA and nattokinase in the SHR (2 g/kg; SHD); Group 2,
medium dose of GABA and nattokinase in the SHR (1.2 g/kg;
SMD); Group 3, low dose of GABA and nattokinase in the SHR
(0.4 g/kg; SLD); Group 4, negative control in the SHR (SD);
Group 5, positive control (SM); Group 6, high dose of GABA and
nattokinase in the WKY (2 g/kg) (WHD); and Group 7, negative
control in the WKY (WD). Distilled water served as the nega-
tive control, and captopril (50mg/kg), a known ACEI, served as
the positive control. All the rats were orally administered by
gastric intubation. During the experimental period, food
intake and body weight were recorded once per week.
2.3. Data collection
2.3.1. Blood sampling
After 8 weeks, the ratswere sacrificed, and blood sampleswere
collected from the abdominal aorta into heparinized tubes to
measure total cholesterol, triacylglycerol, high density lipo-
protein, low density lipoprotein, uric acid, Na, K, and Cl. The
blood was immediately centrifuged (600g for 5 minutes), and
then plasma samples were stored at 4C until analysis.
2.3.2. Blood pressure
We measured the SBP, the DBP, and the heart rate (HR) of the
rats using the tail-cuff method with a BP-98A (Softron, Tokyo,
Japan) once per week. Before themeasurements, the rats wereTable 2 e Effect of oral administration of GABA and nattokinas
TG (mg/dL) TC (mg/dL) HDL (mg/dL)
SHD 64.5  0.778b 48.5  0.707a 24.0  0.707b
SMD 59.0  0.414b 43.5  0.707a 22.5  0.707bc
SLD 61.5  0.192b 37.0  0.828a 22.5  0.707bc
SD 62.5  0.778b 53.0  0.556a 21.0  0.121c
SM 59.0  0.414b 43.5  0.607a 21.0  0.414c
WHD 102.5  0.607a 56.5  0.364a 33.5  0.707a
WD 101.5  0.707a 58.0  0.485a 32.0  0.414a
Different letters indicate a significant difference (p < 0.05, mean  SD).
GABA ¼ g-aminobutyric acid; HDL¼ high-density lipoprotein; LDL¼ low-d
of GABA and nattokinase in the SHR; SLD ¼ low dose of GABA and nattok
SHR; SMD ¼ medium dose of GABA and nattokinase in the SHR; TC ¼ to
control in the WKY; WHD ¼ high dose of GABA and nattokinase in the Wmaintained at 30C for 10 minutes to make the pulsations of
the tail arteries detectable.
2.4. Statistical analysis
The results are expressed as the means with standard errors
for a minimum of six rats. All data are reported as
means  standard deviation. One-way analysis of variance
with Duncan’s post hoc test was used to analyze the data, and
statistical significance was accepted at p < 0.05 (SAS Software;
SAS Institute Inc., Cary, NC, USA).3. Results
3.1. Body weight and feeding efficiency
Table 1 lists the average values of dietary consumption and
body weight gain of the rats for 1 week after the beginning of
treatment using the continuous oral administration test. Each
average value of dietary consumption was significantly
different from that of the control group. However, the gain in
body weight for each treatment group was also significantly
different from that of the control group.
3.2. Effect on the content of serum lipids
In the blood analysis, there was no significant difference
observed for both total cholesterol and low density lipoprotein
among all seven groups (Table 2). However, a significant dif-
ference between the SHR and WKY groups was observed for
triacyglycerols. There was also a significant differencee on serum lipids.
LDL (mg/dL) HDL/LDL (mg/dL) UA (mg/dL)
4.0  0.414a 6.0 2.1  0.243bc
4.5  0.707a 5.0 1.9  0.141c
4.0  0.121a 5.6 2.3  0.424bc
3.5  0.707a 6.0 3.6  0.919a
3.5  0.707a 6.0 2.0  0.141bc
5.5  0.707a 6.1 2.2  0.141bc
5.5  0.707a 5.8 3.0  0.283ab
ensity lipoprotein; SD¼ negative control in the SHR; SHD ¼ high dose
inase in the SHR; SM ¼medium dose of GABA and nattokinase in the
tal cholesterol; TG ¼ triacyglycerols; UA ¼ uric acid; WD ¼ negative
KY.
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and WD groups) and SHD groups. Additionally, the SMD and
SLD groups showed no significant differences from the SHD,
SM, and SD groups, but the SHD group was significantly
different from the SM and SD groups, as shown in Table 2. The
content of uric acid can be ranked highest to lowest as
SD >WD > SLD >WHD > SHD > SM > SMD.
3.3. Effect on the content of minerals
The content of serum sodium, potassium, and chloride
remained stable, as shown in Fig. 1. Despite the considerable
skepticism that remains among some scientists concerning the
relationship between sodium and BP, there is compelling
epidemiological evidence to support a relationship between di-
etary sodium intake and BP and the cardiovascular conse-
quences [8]. Interventional studies have provided further
confirmation of this relationship [9] and have led to the recom-
mendation that dietary sodium intake be restricted in hyper-
tensive patients. Independent of the effects of potassium on BP,
this ion is known to affect blood vessles [10] and the occurrence
of vascular disease [11]. Chloride intake has also emerged as a
confounding element in some studies of the effect of sodiumon
BP, similar to that previously described for potassium [12]. The
effect of GABA and nattokinase on the serum content of these
mineralelements reflectedtheplausiblemechanismof lowering
BP. On the basis of the theory of the renineangiotensin system,
an increase in the level of Ang II would increase the concentra-
tion of Naþ, whereas the intake of ACEI would decrease the
formation of Ang II; thus, the concentration of Naþ decreased.
This result suggested that the antihypertensive effect of pep-
tides from food proteins on the BP of SHRwasmost likely due to
the improvement or regulation of the salt balance in addition to
the simplicity of the inhibition of ACE from this perspective.
3.4. BP and heartbeat
Fig. 2 presents the time courses of the SBP values after the
daily intake of GABA and nattokinase. Whereas the SBP levelsFig. 1 e Concentration of serum cation of spontaneously
hypertensive rats (SHR) after different treatments. Values
are the means with standard errors for six animals per
group. aNo significant difference was observed in each
group (p< 0.05).decreased from negative baseline control values during the
intake period in the SHD group, these levels did not similarly
change in the SMD and SLD groups.
The decreases observed in the SBP levels at 5 weeks,
6 weeks, 7 weeks, and 8 weeks after GABA and nattokinase
intake were 13.67 mmHg, 23.67 mmHg, 22.5 mmHg, and
19.83 mmHg, respectively. These changes differed signifi-
cantly from those of the SD group.
The DBP levels decreased significantly different from the
SD group by 32.5 mmHg (p < 0.05) after 4 weeks of consuming
GABA and nattokinase (Fig. 3A). In the SMD and SLD groups,
the observed decrease was 12.17 mmHg and 1.00 mmHg,
respectively. The reduction in the mean blood pressure (MBP)
values of the SHD group differed significantly from the SD
group after 5 weeks, 6 weeks, 7 weeks, and 8 weeks by
11.66 mmHg (p < 0.05), 19.67 mmHg (p < 0.05), 24.00 mmHg
(p < 0.05), and 29.5 mmHg (p < 0.05), respectively. By contrast,
this parameter did not change significantly in the SMD and
SLD groups throughout the intake period.
After 4 weeks of intake by the SHD group, the MBP values
decreased by at least 26.33mmHg, as shown in Fig. 4A, and the
values increased with time during the intake period. By
comparison, GABA and nattokinase did not cause a change in
the values of SBP (Fig. 2B), DBP (Fig. 3B), andMBP (Fig. 4B) in the
WHD group. In addition, HR did not change significantly in
either group at any point.4. Discussion
The SHR and WKY rats were fed the same diet but showed
significant differences in food intake, and the body weights of
the SHR were significantly lower. Feeding efficiency in hy-
pertensive rats may be caused by excitation of the peripheral
sympathetic nervous system [13,14].
In the present study, GABA and nattokinase had no blood
lipids or electrolytes. Although there is a report showing that
captopril may elevate blood Na level, the IC50 of the drug was
much lower than the GABA and nattokinase used in the pre-
sent study.
The SHR of the negative control groups showed a gradual
increase in SBP and DBP values from weaning that reached
maxima at 8 weeks of life. From this age, the arterial BPs of the
rats remained consistently high, and their DBP values were
similar to those of Week 4. A clear decrease in the SBP and DBP
values could be observed in the rats of thepositive control group
treatedwith captopril fromthe5thweek to the 8thweekof life. In
these animals, both the SBP and DBP values remained constant
during thisperiod.The antihypertensiveeffect of theseproducts
was less pronounced than that of the pharmacological treat-
ment but could be clearly observed from the 5th week to the 8th
week of life.
It was not surprising to find a clear decrease in SBP and DBP
values upon administering 50 mg/kg of captopril to SHR
because this drug is a potent ACEIwith an IC50 value of 0.02 mM
[15]. In this context, Fujita and Yoshikawa [15] suggested that,
compared with captopril, the ACEIs derived from food protein
possess higher in vivo activities than those expected from their
in vitroactivities, and that this result couldbeexplainedby their
higher affinity for the tissues and by their slower elimination.
Fig. 2 e Effect of a single oral administration of g-aminobutyric acid (GABA) and nattokinase on systolic blood pressure (SBP)
values in (A) spontaneously hypertensive rats and (B) WistareKyoto rats. Symbols:-, SHD;,, SMD;:, SLD; 3, SD;;, SM;
B, WHD;C, WD. Values are means with standard errors for six animals per group. Mean values were significantly different
from the control value at the same time point: p< 0.05. SD [ negative control in the SHR; SHD [ high dose of GABA and
nattokinase in the SHR; SLD[ low dose of GABA and nattokinase in the SHR; SM[medium dose of GABA and nattokinase
in the SHR; SMD [ medium dose of GABA and nattokinase in the SHR; WD [ negative control in the WKY; WHD [ high
dose of GABA and nattokinase in the WKY.
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from the protein of the beans by B. subtilis B060, which has
high productivity of GABA and nattokinase. With respect to
GABA production, acidic fermented beans are beneficial
because the glutamate decarboxylase activity of B. subtilis
B060 is optimal at a pH of approximately 7 (Suwanmanon and
Hsieh, unpublished results). Its GABA transaminase (optimal
pH 7e10) [16], which catalyzes the transformation of GABA to
succinic semialdehyde, is poorly active under acidic condi-
tions. Therefore, GABA accumulates during fermentation.
Although the mechanism underlying the hypotensive ac-
tion of systemically administered GABA has not yet been fully
elucidated, several hypotheses have been postulated. One ofFig. 3 e Effect of a single oral administration of GABA and natto
spontaneously hypertensive rats and (B) WistareKyoto rats. Sym
WD. Values are means with standard errors for six animals pe
control value at the same time point: p< 0.05. GABA[ g-amino
dose of GABA and nattokinase in the SHR; SLD [ low dose of G
GABA and nattokinase in the SHR; SMD[medium dose of GABA
WKY; WHD [ high dose of GABA and nattokinase in the WKY.them is as follows. Because GABA hardly passes the bloode-
brain barrier [17,18], this molecule acts not in the central
nervous system but in the peripheral nervous system.
Recently, a few studies have reported that various dietary
materials or products containing GABA decreased BP values in
hypertensive patients in Japan. Gabaron tea, extracts of Beni-
Koji, and a particular germ of rice [19] were included among
these supplements. However, these dietary materials or
products contain many ingredients in addition to GABA, and
although their effects were not ruled out, it was presumed
that the hypotensive effect was due to the presence of GABA.
Nattokinase has been investigated as a strong fibrinolytic
enzyme in vitro and in vivo [7,20e22]. Recent studies havekinase on diastolic blood pressure (DBP) values in (A)
bols:-, SHD;,, SMD;:, SLD; 3, SD;;, SM; B, WHD;C,
r group. Mean values were significantly different from the
butyric acid; SD[ negative control in the SHR; SHD[ high
ABA and nattokinase in the SHR; SM [ medium dose of
and nattokinase in the SHR; WD[ negative control in the
Fig. 4 e Effect of a single oral administration of GABA and nattokinase on mean blood pressure (MBP) values in (A)
spontaneously hypertensive rats and (B) WistareKyoto rats. Symbols:-, SHD;,, SMD;:, SLD; 3, SD;;, SM; B, WHD;C,
WD. Values are means with standard errors for six animals per group. Mean values were significantly different from the
control value at the same time point: p< 0.05. GABA[ g-aminobutyric acid; SD[ negative control in the SHR; SHD[ high
dose of GABA and nattokinase in the SHR; SLD [ low dose of GABA and nattokinase in the SHR; SM [ medium dose of
GABA and nattokinase in the SHR; SMD[medium dose of GABA and nattokinase in the SHR; WD[ negative control in the
WKY; WHD [ high dose of GABA and nattokinase in the WKY.
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ing nattokinase decreases both SBP and DBP in hypertensive
patients [5]. However, the mechanism by which nattokinase
prevents hypertension has yet to be elucidated.
Several reports have noted that B. subtilis produces and
secretes enzymes such as subtilisin [23], metalloproteases
[24], Epr [25], Mpr [26], Vpr [27], bacillopeptidase F [28,29], and
b-glucanase [30]. Nattokinase also digests cross-linked fibrin
directly at a concentration of 0.02mg/mL [21] and prolongs the
coagulation time of plasma in parallel with the degradation of
fibrinogen in rats with intraduodenal administration (80 mg/
kg body weight) [7]. These reports suggest that the fibrinolytic
and antithrombotic effects of nattokinase are similar or su-
perior to those of bacillopeptidase F. Bacillopeptidase F con-
tains the residues Val101eAla102ePro103, which corresponds to
the ACE-inhibitory tripeptide ValeAlaePro, and does not
contain the renin-inhibitory dipeptide, TyreTyr [29].
In conclusion, the daily intake of fermented beans con-
taining GABA andnattokinasemay be helpful in controlling BP
levels in hypertensive model animals. Nattokinase, whether
intact or fragmented, is absorbed intestinally and reduces
hypertension in SHR. Nevertheless, there are different
mechanisms on antihypertensive effects depending on the
formof oral administration. Nattokinase retaining its protease
activity may lower BP through the decrease of blood viscosity
by cleaving plasma fibrinogen. GABA is present in many veg-
etables and fruits. The low incidence of hypertension among
vegetarians, therefore, may be partly attributable to their
ingestion of GABA via these foods. Moreover, GABA and nat-
tokinase were contained in food ingested daily and thus meet
the requirement for naturalness and safety.Conflicts of interest
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